Recent

% | $
Quotes you view appear here for quick access.

NUO THERAPEUTİCS, AŞ Message Board

  • donnyboyko donnyboyko Apr 22, 2013 8:00 AM Flag

    Our Team...

    Martin Rosendale, Chief Executive Officer
    Mr. Rosendale joined Cytomedix, Inc. in March 2008 as COO and he was appointed Chief Executive Officer in July 2008. Prior to joining Cytomedix, Mr. Rosendale was Chief Executive Officer of Core Dynamics, Inc. where he managed their Israel based R&D program and initiated U.S. commercial operations for cryobiology and cell lyophilization technologies. Mr. Rosendale has more than 24 years of specialty medical experience. He has held leadership positions for the past 15 years with American Red Cross, SangStat, North American Vaccine and ZLB Bioplasma, in addition to serving on the boards of the Transplant Recipients International Organization and the American Red Cross Biomedical Services, San Jose Region. Mr. Rosendale earned a Bachelor of Science degree in Microbiology from California State University.
    Edward L. Field, Chief Operating Officer
    Ed Field has been employed at Cytomedix since February 2012. Aldagen since November 2004. Prior to joining Aldagen, Mr. Field was the President and Chief Executive Officer of Inologic, Inc., a private biopharmaceutical company, from 2002 to September 2004. Prior to joining Inologic, from 1999 to 2002, Ed was the President of Molecumetics, Ltd., a drug discovery and development subsidiary of Tredegar Corporation, until its merger with Therics, LLC, a regenerative medicine company. Ed received a Master of Business Administration degree from the University of Virginia's Darden School of Business Administration and a Bachelor of Science degree in Economics from Duke University.

    Peter A. Clausen, Ph.D., Vice President, Business Development\
    Dr. Clausen joined Cytomedix, Inc. in September 2008 after consulting tothe Company since May2008. Prior to joining Cytomedix, Dr. Clausen was a founding member and Vice President,Research and Development at Marligen Bioscience, a biotechnology company that develops,manufactures and markets innovative products for the life sciences market. Dr. Clausenis a seasoned biochemist with nearly 15 years experience in the biotechnology sector. Dr. Clausen completed his post-doctoral training in the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned a Bachelor of Science degree in Biochemistry from Beloit College and a Ph.D. in Biochemistry from Rush University.
    Carelyn P. Fylling, R.N., M.S.N., C.W.S, C.L.N.C., Vice President, Professional Services
    Ms. Fylling joined Cytomedix, Inc. in December 2001. Prior to Cytomedix,Ms. Fylling was recruited to start Curative Health Services, a biotechnology company specializing in the production of autologous platelet releasates for the management of chronic wounds. Since 1986, Ms. Fylling has been instrumental in developing point-of-care PRP systems, conducting clinical/outcome studies in chronic wounds, publishing and presenting on PRP, designing a national wound database, and training physicians and nurses in comprehensive wound management. She currently serves on the Board of Directors of the Association for the Advancement of Wound Care. She received her Bachelor of Science Degreein Nursing from North Park College, Chicago, IL and her Master of Science in Nursing from the University of California, San Francisco, Ca.
    Cathryn J Hope, Vice President of Marketing
    Ms. Hope joined Cytomedix, Inc. in January 2012 after consulting to the Company since May 2008. She brings to Cytomedix more than 24 years of International marketing and product commercialization experience in biologics. Prior to joining Cytomedix, Ms. Hope was responsible for the Immunology commercial portfolio at Talecris Biotherapeutics (previously Bayer Biologics). Prior to joining Talecris, Cathryn was Director of Marketing for CSL Behring where she helped launch the US plasma products division of Australian based CSL Limited. Ms. Hope received a Bachelor of Science degree in Immunology from Melbourne University, Australia, and went on to complete a Bachelor of Marketing from the Melbourne Business School/Charles Sturt University, Australia.
    David Jorden, Executive Board Director & Investor Relations
    Mr. Jorden joined Cytomedix, Inc. in September 2008. He brings to Cytomedix more than 20 years of public and private company investment experience. Prior to joining Cytomedix, Mr. Jorden was responsible for equity portfolio management at Morgan Stanley's Private Wealth Management group and previously served as CFO at Genometrix, Inc., a private genomics/life sciences company. Mr. Jorden serves on the Board of Opexa Therapeutics, Inc., PLx Pharma, Inc., and DLush, a San Diego based deluxe beverage company. Mr. Jorden earned a Master of Management from the Kellogg School of Management at Northwestern University and a BBA from the University of Texas at Austin. He holds both CFA and CPA designations.

    Patrick P. Vanek, R.Ph., Vice President, Operations
    Patrick Vanek joined Cytomedix, Inc. in July 2010. He brings to Cytomedix more than 30 years of diverse technical and managerial experience in pharmaceuticals and medical devices, specifically Formulation Design, Process Development, QA/QC and Supply Chain/Logistics. Prior to joining Cytomedix, Mr. Vanek spent 12 years at Otsuka America Pharmaceutical, Inc. where he rose through a number of managerial positions to become Vice President of Technical Operations. Prior to that, he held various development/technical management positions at KV Pharmaceutical Corp., Teva Pharmaceuticals USA, Wyeth Laboratories and McNeil Pharmaceutical. Mr. Vanek earned a B.S. in Pharmacy from the Philadelphia College of Pharmacy & Science and is a Registered Pharmacist.
    David Jorden, Executive Chairman
    David E. Jorden, CPA, CFA has served as a Director since September 19, 2008. From 2003 to 2008, he was with Morgan Stanley's Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a M.M. from Northwestern University's Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr. Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA). He is also on the board of two private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs), and DLush, LLC, a San Diego based deluxe beverage retail concept.



    James Benson, Principal Director
    James S. Benson has served as a Director since November 1, 2004. Mr. Benson has over 25 years of experience in the healthcare industry, and also serves as a director of Cryolife, Inc., and Medical Device Consultants, Inc. Mr. Benson retired from the Advanced Medical Device Association (Advamed) where he served as executive vice president for technical and regulatory affairs. Prior to that, he held numerous senior positions at the Food and Drug Administration (''FDA'') over a twenty year period. He retired from the FDA as director of the Center for Devices and Radiological Health (CDRH). Earlier, he served as deputy commissioner of the FDA, and also as its commissioner for a one-year period. Mr. Benson earned a B.S. degree in civil engineering from the University of Maryland and a M.S. degree in nuclear engineering from the Georgia Institute of Technology.



    Martin Rosendale, Chief Executive Officer
    Martin P. Rosendale has served as our Chief Executive Officer and Director since July 1, 2008. Prior to that, in March 2008, he was appointed as Executive Vice-President and Chief Operating Officer of the Company. From January 2005 to March 2008, Mr. Rosendale held the position of Chief Executive Officer of Core Dynamics, Inc., a Rockville, MD biotechnology startup company using cryopreservation technology developed in Israel. From March 2001 to December 2004, Mr. Rosendale held the position of Senior Vice President and General Manager of ZLB Bioplasma, Inc., a Glendale, CA biologics company, as well as other positions at various biotechnology companies. Mr. Rosendale holds a Bachelor of Science degree in Microbiology from California State University in Long Beach, CA (1982).



    Joe Del Guercio, Director
    Mr. Del Guercio has served as a Director since February 8, 2012. Previously, he was an Observer for the Aldagen board of directors. Mr. Del Guercio joined CNF Investments in 2004 as a Managing Director. Prior to joining CNF, Mr. Del Guercio was a director with LPL Financial Services, a Boston and San Diego based independent broker dealer, with responsibility for strategic planning, new product development, and acquisitions. Prior to LPL, Mr. Del Guercio was with Robertson Stephens and Goldman Sachs, where he focused on mergers and acquisitions, private and public equity financings, and restructurings. Mr. Del Guercio serves on the boards of Vital Sensors, Verax Biomedical, Overture Technologies, Vision Chain, and DigitalBridge Communications. Mr. Del Guercio is also a board observer with Lipomics Technologies Inc., TerraGo Technologies and Innovative Biosensors, and is an advisory board member on a number of CNF’s fund investments. Mr. Del Guercio has an M.B.A. from Harvard Business School and a B.S. from Boston College.



    Stephen N. Keith, M.D., Director
    Stephen N. Keith, M.D., M.S.P.H. has served as a Director since September 19, 2008. Dr. Keith is the President and Chief Operating Officer of Panacea Pharmaceuticals, Inc.. From 2005 to 2006, Dr. Keith served as Senior Consultant at Biologics Consulting Group, LLC, a biopharmaceutical consulting company. From 2003 to 2005, he was Managing Director at Glocap Advisors LLC, a division of Glocap Funding LLC, an investment banking firm. Dr. Keith has held a range of senior management positions in the pharmaceutical and biotechnology industries, including President and Chief Operating Officer at Antex Biologics Inc., and Vice President, Marketing and Sales at North American Vaccine, Inc., Dr. Keith also serves as Chairman of the Board of Directors of NanoVec, Inc., an early-stage biopharmaceutical company. Dr. Keith holds an undergraduate degree magna cum laude from Amherst College in Massachusetts (1973), a degree in medicine from University of Illinois, College of Medicine, (1977) and a Master of Science in Public Health degree from the University of California, Los Angeles (1982). He is a licensed physician in the states of California and Maryland. Dr. Keith is a Fellow of the Academy of Pediatrics and a Diplomate of the American Board of Pediatrics.



    Richard Kent, M.D., Director
    Dr. Kent has served as a Director since February 8, 2012. Previously, he was a member of the Aldagen board of directors from March 2010- February 2012. Since 2008, he has been a Venture Partner with Intersouth Partners, a venture capital firm. Dr. Kent served as the President and Chief Executive Officer of Serenex, Inc., a biotechnology company focused on oncology, from 2002 until its sale to Pfizer in April 2008. Prior to joining Serenex, he served as President and Chief Executive Officer of Ardent Pharmaceuticals, Inc. and held senior executive positions at GlaxoSmithKline, Glaxo Wellcome, and Burroughs Wellcome. Dr. Kent has served as a director of Inspire Pharmaceuticals, Inc., a publicly traded biotechnology company, since June 2004. Dr. Kent received his undergraduate degree from the University of California, Berkely and his M.D. from the University of California, San Diego. He is board certified in both internal medicine and cardiology.



    Lyle A. Hohnke, Ph.D., Director

    Dr. Hohnke has served as a Director since February 8, 2012. Previously, he served as Aldagen's Chief Executive Officer since 2011 and as a Director on Aldagen's Board from August 2008- February 2012. He has been a partner of Tullis Dickerson, a healthcare-focused venture capital fund, since 1994. Dr. Hohnke holds Ph.D. and M.A. degrees from the University of Oregon and was a postdoctoral fellow at the UCLA School of Medicine. He holds an M.B.A. from the Hartford Graduate Institute at Rensselaer Polytechnic Institute and a B.A. degree from Western Michigan University.
    Mark T. McLoughlin, Director
    Mark T. McLoughlin has served as a Director since June 7, 2004. Mr. McLoughlin currently serves as a Senior Vice President for VWR International, a global distributor of laboratory supplies, equipment and services to the pharma, biotech, industrial and clinical laboratory. In this capacity, he has responsibility for the sourcing and marketing functions for North America. Prior to joining VWR International, he was Senior Vice President, Chief Marketing Officer for Cardinal Health based in Rolle, Switzerland. Prior to joining Cardinal, he was vice president of commercial operations for Norwood Abbey Ltd., an Australian-based medical technology company. Earlier, he was President of North American operations for Ion Beam Application, Inc., a Belgium-based global medical technology company. His executive career experience also includes Mallinckrodt, as well as positions with other healthcare companies.



    C. Eric Winzer, Director
    C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer currently serves as Executive Vice President and Chief Financial Officer of Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX). Prior to joining Avalon, Mr. Winzer was with Life Technologies Corporation (Nasdaq: LIFE), formerly Invitrogen Corporation, a provider of life science technologies for disease research and drug discovery, from 2000 to 2006, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life's ERP implementation and VP, Finance. From 1986 to 2000, Mr. Winzer held various positions of increasing responsibilities at Life Technologies, Inc., including Chief Financial Officer, Secretary and Treasurer. From 1980 until 1986 he held various financial positions at Genex Corporation. Mr. Winzer received his B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary's University.
    David Jorden, Executive Chairman
    David E. Jorden, CPA, CFA has served as a Director since September 19, 2008. From 2003 to 2008, he was with Morgan Stanley's Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a M.M. from Northwestern University's Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr. Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA). He is also on the board of two private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs), and DLush, LLC, a San Diego based deluxe beverage retail concept.

    James Benson, Principal Director
    James S. Benson has served as a Director since November 1, 2004. Mr. Benson has over 25 years of experience in the healthcare industry, and also serves as a director of Cryolife, Inc., and Medical Device Consultants, Inc. Mr. Benson retired from the Advanced Medical Device Association (Advamed) where he served as executive vice president for technical and regulatory affairs. Prior to that, he held numerous senior positions at the Food and Drug Administration (''FDA'') over a twenty year period. He retired from the FDA as director of the Center for Devices and Radiological Health (CDRH). Earlier, he served as deputy commissioner of the FDA, and also as its commissioner for a one-year period. Mr. Benson earned a B.S. degree in civil engineering from the University of Maryland and a M.S. degree in nuclear engineering from the Georgia Institute of Technology.

    Martin Rosendale, Chief Executive Officer
    Martin P. Rosendale has served as our Chief Executive Officer and Director since July 1, 2008. Prior to that, in March 2008, he was appointed as Executive Vice-President and Chief Operating Officer of the Company. From January 2005 to March 2008, Mr. Rosendale held the position of Chief Executive Officer of Core Dynamics, Inc., a Rockville, MD biotechnology startup company using cryopreservation technology developed in Israel. From March 2001 to December 2004, Mr. Rosendale held the position of Senior Vice President and General Manager of ZLB Bioplasma, Inc., a Glendale, CA biologics company, as well as other positions at various biotechnology companies. Mr. Rosendale holds a Bachelor of Science degree in Microbiology from California State University in Long Beach, CA (1982).

    Joe Del Guercio, Director
    Mr. Del Guercio has served as a Director since February 8, 2012. Previously, he was an Observer for the Aldagen board of directors. Mr. Del Guercio joined CNF Investments in 2004 as a Managing Director. Prior to joining CNF, Mr. Del Guercio was a director with LPL Financial Services, a Boston and San Diego based independent broker dealer, with responsibility for strategic planning, new product development, and acquisitions. Prior to LPL, Mr. Del Guercio was with Robertson Stephens and Goldman Sachs, where he focused on mergers and acquisitions, private and public equity financings, and restructurings. Mr. Del Guercio serves on the boards of Vital Sensors, Verax Biomedical, Overture Technologies, Vision Chain, and DigitalBridge Communications. Mr. Del Guercio is also a board observer with Lipomics Technologies Inc., TerraGo Technologies and Innovative Biosensors, and is an advisory board member on a number of CNF’s fund investments. Mr. Del Guercio has an M.B.A. from Harvard Business School and a B.S. from Boston College.

    Stephen N. Keith, M.D., Director
    Stephen N. Keith, M.D., M.S.P.H. has served as a Director since September 19, 2008. Dr. Keith is the President and Chief Operating Officer of Panacea Pharmaceuticals, Inc.. From 2005 to 2006, Dr. Keith served as Senior Consultant at Biologics Consulting Group, LLC, a biopharmaceutical consulting company. From 2003 to 2005, he was Managing Director at Glocap Advisors LLC, a division of Glocap Funding LLC, an investment banking firm. Dr. Keith has held a range of senior management positions in the pharmaceutical and biotechnology industries, including President and Chief Operating Officer at Antex Biologics Inc., and Vice President, Marketing and Sales at North American Vaccine, Inc., Dr. Keith also serves as Chairman of the Board of Directors of NanoVec, Inc., an early-stage biopharmaceutical company. Dr. Keith holds an undergraduate degree magna cum laude from Amherst College in Massachusetts (1973), a degree in medicine from University of Illinois, College of Medicine, (1977) and a Master of Science in Public Health degree from the University of California, Los Angeles (1982). He is a licensed physician in the states of California and Maryland. Dr. Keith is a Fellow of the Academy of Pediatrics and a Diplomate of the American Board of Pediatrics.

    Richard Kent, M.D., Director
    Dr. Kent has served as a Director since February 8, 2012. Previously, he was a member of the Aldagen board of directors from March 2010- February 2012. Since 2008, he has been a Venture Partner with Intersouth Partners, a venture capital firm. Dr. Kent served as the President and Chief Executive Officer of Serenex, Inc., a biotechnology company focused on oncology, from 2002 until its sale to Pfizer in April 2008. Prior to joining Serenex, he served as President and Chief Executive Officer of Ardent Pharmaceuticals, Inc. and held senior executive positions at GlaxoSmithKline, Glaxo Wellcome, and Burroughs Wellcome. Dr. Kent has served as a director of Inspire Pharmaceuticals, Inc., a publicly traded biotechnology company, since June 2004. Dr. Kent received his undergraduate degree from the University of California, Berkely and his M.D. from the University of California, San Diego. He is board certified in both internal medicine and cardiology.

    Lyle A. Hohnke, Ph.D., Director
    Dr. Hohnke has served as a Director since February 8, 2012. Previously, he served as Aldagen's Chief Executive Officer since 2011 and as a Director on Aldagen's Board from August 2008- February 2012. He has been a partner of Tullis Dickerson, a healthcare-focused venture capital fund, since 1994. Dr. Hohnke holds Ph.D. and M.A. degrees from the University of Oregon and was a postdoctoral fellow at the UCLA School of Medicine. He holds an M.B.A. from the Hartford Graduate Institute at Rensselaer Polytechnic Institute and a B.A. degree from Western Michigan University.

    Mark T. McLoughlin, Director
    Mark T. McLoughlin has served as a Director since June 7, 2004. Mr. McLoughlin currently serves as a Senior Vice President for VWR International, a global distributor of laboratory supplies, equipment and services to the pharma, biotech, industrial and clinical laboratory. In this capacity, he has responsibility for the sourcing and marketing functions for North America. Prior to joining VWR International, he was Senior Vice President, Chief Marketing Officer for Cardinal Health based in Rolle, Switzerland. Prior to joining Cardinal, he was vice president of commercial operations for Norwood Abbey Ltd., an Australian-based medical technology company. Earlier, he was President of North American operations for Ion Beam Application, Inc., a Belgium-based global medical technology company. His executive career experience also includes Mallinckrodt, as well as positions with other healthcare companies.

    C. Eric Winzer, Director
    C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer currently serves as Executive Vice President and Chief Financial Officer of Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX). Prior to joining Avalon, Mr. Winzer was with Life Technologies Corporation (Nasdaq: LIFE), formerly Invitrogen Corporation, a provider of life science technologies for disease research and drug discovery, from 2000 to 2006, where he served as Senior VP and Chief Financial Officer, Executive Sponsor for Life's ERP implementation and VP, Finance. From 1986 to 2000, Mr. Winzer held various positions of increasing responsibilities at Life Technologies, Inc., including Chief Financial Officer, Secretary and Treasurer. From 1980 until 1986 he held various financial positions at Genex Corporation. Mr. Winzer received his B.A. in Economics and Business Administration from McDaniel College and an M.B.A. from Mount Saint Mary's University.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies